Background Somatostatin analogues (SA) are currently used to prevent postoperative
pancreatic fistula (POPF) development. However, its use is controversial. This study …

Background Prophylactic administration of somatostatin analogues (SA) to reduce the
incidence of post-operative pancreatic fistula (POPF) remains contentious. This meta …

Background Post-operative pancreatic fistula (POPF) is a common complication of
pancreatic resection. Somatostatin analogues (SA) have been used as prophylaxis to …

Background: The use of somatostatin analogues (SAs) following pancreaticoduodenectomy
(PD) is controversial. Method: Literature databases were searched systematically for …

Objective Postoperative pancreatic fistula/POPF is the most feared complication in
pancreatic surgery. Although several systematic reviews investigated the impact of …

Background Prophylactic somatostatin to reduce the incidence of clinically relevant
postoperative pancreatic fistula after pancreaticoduodenectomy remains controversial. We …

Background Clinically relevant postoperative pancreatic fistula (CR-POPF) is a significant
contributor to morbidity after pancreatectomy. Somatostatin analogues have shown variable …

Objective: Pharmacological prevention of postoperative pancreatic fistula (POPF) after
pancreatectomy is open to debate. The present study compares clinically significant POPF …

Background Leakage from the pancreatic stump is a leading cause of morbidity following
pancreatic surgery. It is essential to evaluate the effect of somatostatin analogues (SAs) …

Background The benefit of somatostatin for the prevention of pancreatic fistula has been
debated widely in the literature. The aim of this study was to evaluate the efficacy of …